K-ras mutations and anti-EGFr antibody therapy
US11155876B2 · kind B2 · utility
0Cited by
4References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 21, 2018 |
| Grant date | Oct 26, 2021 |
| Priority date | — |
| Expiry date | Sep 19, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/118
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present application relates to K-ras mutations, to polynucleotides encoding mutant K-ras polypeptides, and to methods of identifying K-ras mutations. The present application also relates to methods of diagnosing cancer; and methods and kits for predicting the usefulness of anti-EGFr specific binding agents in the treatment of tumors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.